Free Trial

SEP Acquisition (SEPA) Competitors

$9.25
+0.77 (+9.08%)
(As of 03:46 PM ET)

SEPA vs. MAQC, NVNO, SWSS, PDEX, STIM, SRTS, MGRM, AMIX, HSAQ, and ICCM

Should you be buying SEP Acquisition stock or one of its competitors? The main competitors of SEP Acquisition include Maquia Capital Acquisition (MAQC), enVVeno Medical (NVNO), Clean Energy Special Situations (SWSS), Pro-Dex (PDEX), Neuronetics (STIM), Sensus Healthcare (SRTS), Monogram Orthopaedics (MGRM), Autonomix Medical (AMIX), Health Sciences Acquisitions Co. 2 (HSAQ), and IceCure Medical (ICCM).

SEP Acquisition vs.

SEP Acquisition (NASDAQ:SEPA) and Maquia Capital Acquisition (NASDAQ:MAQC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.

In the previous week, Maquia Capital Acquisition had 1 more articles in the media than SEP Acquisition. MarketBeat recorded 1 mentions for Maquia Capital Acquisition and 0 mentions for SEP Acquisition. SEP Acquisition's average media sentiment score of 0.00 equaled Maquia Capital Acquisition'saverage media sentiment score.

Company Overall Sentiment
SEP Acquisition Neutral
Maquia Capital Acquisition Neutral

3.7% of SEP Acquisition shares are owned by institutional investors. Comparatively, 12.4% of Maquia Capital Acquisition shares are owned by institutional investors. 20.0% of SEP Acquisition shares are owned by company insiders. Comparatively, 78.4% of Maquia Capital Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SEP Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Maquia Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

SEP Acquisition has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, Maquia Capital Acquisition has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SEP AcquisitionN/AN/A-$2.36MN/AN/A
Maquia Capital AcquisitionN/AN/A-$960KN/AN/A

Company Net Margins Return on Equity Return on Assets
SEP AcquisitionN/A N/A -16.47%
Maquia Capital Acquisition N/A N/A -5.09%

SEP Acquisition and Maquia Capital Acquisition both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
SEP AcquisitionN/AN/A
Maquia Capital AcquisitionN/AN/A

Summary

Maquia Capital Acquisition beats SEP Acquisition on 5 of the 6 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SEPA vs. The Competition

MetricSEP AcquisitionSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$49.04M$3.90B$4.93B$7.99B
Dividend YieldN/A1.96%44.82%3.91%
P/E RatioN/A8.38117.6214.81
Price / SalesN/A72.072,468.4573.68
Price / CashN/A47.4332.2329.27
Price / Book-13.404.395.024.56
Net Income-$2.36M$4.26M$101.60M$212.43M
7 Day Performance-22.50%2.38%5.41%4.87%
1 Month Performance0.72%7.74%9.46%9.25%
1 Year Performance-15.26%16.73%9.72%10.45%

SEP Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MAQC
Maquia Capital Acquisition
0 of 5 stars
$11.06
flat
N/AN/A$68.35MN/A0.004Upcoming Earnings
NVNO
enVVeno Medical
0.019 of 5 stars
$5.10
+0.8%
N/A+30.6%$67.93MN/A-2.6619Positive News
SWSS
Clean Energy Special Situations
0 of 5 stars
$10.54
-1.5%
N/AN/A$73.89MN/A0.002,021Positive News
PDEX
Pro-Dex
0 of 5 stars
$18.70
+4.5%
N/A+11.0%$63.95M$46.09M32.24145Positive News
STIM
Neuronetics
2.4295 of 5 stars
$2.55
-1.9%
$8.00
+213.7%
-3.7%$76.45M$71.35M-2.38203
SRTS
Sensus Healthcare
4.3346 of 5 stars
$3.83
+1.3%
$8.00
+108.9%
+111.8%$62.77M$24.41M127.7135Gap Down
MGRM
Monogram Orthopaedics
0.7262 of 5 stars
$1.90
-3.1%
N/A-84.7%$60.11M$364,999.00-2.4128Earnings Report
AMIX
Autonomix Medical
0 of 5 stars
$3.06
+8.9%
N/AN/A$57.50MN/A0.001Gap Up
HSAQ
Health Sciences Acquisitions Co. 2
0 of 5 stars
$4.98
-5.0%
N/A-65.6%$55.84MN/A0.004
ICCM
IceCure Medical
2.2762 of 5 stars
$1.17
-3.3%
$2.95
+152.1%
-18.1%$53.38M$3.23M-3.5571Upcoming Earnings
News Coverage
Gap Up

Related Companies and Tools

This page (NASDAQ:SEPA) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners